Renaissance Technologies LLC Has $6.89 Million Stock Holdings in Brainsway Ltd. Sponsored ADR $BWAY

Renaissance Technologies LLC increased its position in shares of Brainsway Ltd. Sponsored ADR (NASDAQ:BWAY) by 87.2% during the 1st quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 518,420 shares of the company’s stock after acquiring an additional 241,560 shares during the quarter. Renaissance Technologies LLC’s holdings in Brainsway were worth $6,890,000 as of its most recent SEC filing.

Several other large investors have also recently bought and sold shares of BWAY. Y.D. More Investments Ltd raised its holdings in Brainsway by 136.6% in the first quarter. Y.D. More Investments Ltd now owns 272,004 shares of the company’s stock worth $3,615,000 after purchasing an additional 157,042 shares during the period. Walleye Capital LLC acquired a new position in shares of Brainsway in the 1st quarter valued at $433,000. Sigma Planning Corp grew its holdings in shares of Brainsway by 369.1% in the 1st quarter. Sigma Planning Corp now owns 70,363 shares of the company’s stock valued at $935,000 after buying an additional 55,363 shares during the period. Sei Investments Co. increased its position in shares of Brainsway by 262.5% in the 1st quarter. Sei Investments Co. now owns 226,378 shares of the company’s stock valued at $3,009,000 after buying an additional 163,925 shares in the last quarter. Finally, Commonwealth of Pennsylvania Public School Empls Retrmt SYS bought a new stake in shares of Brainsway in the 1st quarter valued at $232,000. Institutional investors own 30.11% of the company’s stock.

Brainsway Stock Down 0.1%

Shares of NASDAQ:BWAY opened at $15.80 on Wednesday. Brainsway Ltd. Sponsored ADR has a 12 month low of $5.70 and a 12 month high of $17.35. The company’s fifty day simple moving average is $15.05 and its 200 day simple moving average is $14.16. The firm has a market cap of $634.05 million, a price-to-earnings ratio of 45.14 and a beta of 1.24.

Brainsway (NASDAQ:BWAY) last posted its quarterly earnings data on Wednesday, May 13th. The company reported $0.12 EPS for the quarter, beating the consensus estimate of $0.05 by $0.07. The business had revenue of $15.53 million for the quarter, compared to analysts’ expectations of $14.63 million. Brainsway had a net margin of 15.68% and a return on equity of 12.28%. Research analysts expect that Brainsway Ltd. Sponsored ADR will post 0.33 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several research analysts have weighed in on the company. Zacks Research upgraded Brainsway from a “hold” rating to a “strong-buy” rating in a report on Monday, July 13th. Wall Street Zen upgraded Brainsway from a “hold” rating to a “buy” rating in a report on Sunday. BTIG Research initiated coverage on Brainsway in a research report on Monday, July 20th. They set a “buy” rating and a $18.00 price target on the stock. Weiss Ratings reiterated a “buy (b-)” rating on shares of Brainsway in a report on Tuesday, July 21st. Finally, HC Wainwright reiterated a “buy” rating and set a $14.00 price objective on shares of Brainsway in a report on Friday, July 17th. One analyst has rated the stock with a Strong Buy rating and five have assigned a Buy rating to the company. According to data from MarketBeat.com, Brainsway has an average rating of “Buy” and an average price target of $15.67.

About Brainsway

Brainsway Ltd is a medical device company specializing in non-invasive neuromodulation therapies. Publicly traded on the NASDAQ under the symbol BWAY, the company develops and commercializes deep transcranial magnetic stimulation (Deep TMS) systems designed to treat a range of neuropsychiatric and neurological disorders. Brainsway’s technology aims to offer an alternative or complement to traditional pharmacological therapies by targeting precise brain regions with its patented coil designs.

The company’s flagship Deep TMS platform utilizes proprietary H-coil arrays engineered to reach deeper cortical structures than conventional TMS devices.